Nichd: r & d: preclinical development of androgen progestin (pdap): non-severable
Active Awarded Last action
- Contract number
- 75N94026F00003
- Awardee
-
Sri International UEI SRG2J1WS9X63
- Awarding agency
-
National Institute of Child Health and Human Development
National Institutes of Health, Department of Health and Human Services
- Obligated
- $596,758
Award facts
- Contract value 100% obligated
- $596,758.34 Current and potential, with all options
- Completion date 3% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Menlo Park, CA 94025, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
The National Institute of Child Health and Human Development issued a delivery order to Sri International on September 30, 2026, with a ceiling value of $596,758.34 for preclinical development of androgen progestin under a cost-plus-fixed-fee pricing structure.
This is Task Order 3 under a parent indefinite delivery contract for preclinical drug development research. Place of performance is Menlo Park, California. The order extends through September 29, 2028. The work involves preclinical development activities for androgen progestin candidates, a typical scope within NICHD's biomedical research mission and consistent with Sri International's established portfolio in drug candidate development and safety evaluation services.
Sri International is a non-profit research organization headquartered in Menlo Park and operates as a prime contractor on the vast majority of its federal awards. The organization holds substantial indefinite delivery vehicles anchoring task-order activity across NIH institutes, including single-award IDIQs for Interventional Agents Chemistry Services ($50 million) and Interventional Agents Safety and Pharmacokinetics Services ($50 million), both active through September 2032 and supporting drug candidate development and toxicology evaluation. On major research programs, Sri International routinely engages research universities and specialized technical firms as subcontractors for distinct workstreams; Charles River Laboratories frequently appears as a subcontractor for laboratory animal procurement and preclinical services on NIAID and NIDA awards.
Quick answers
Who was awarded contract 75N94026F00003?
75N94026F00003 was awarded to Sri International by National Institute of Child Health and Human Development (National Institutes of Health) on September 30, 2026.
How much is contract 75N94026F00003 worth?
The government has obligated $596,758 on 75N94026F00003.
Is contract 75N94026F00003 an order under another contract?
Yes. 75N94026F00003 is a delivery order under 75N94026D00001, an indefinite delivery contract.
Was contract 75N94026F00003 competed?
The extent of competition for 75N94026F00003 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award